What it is: An investigational weekly dual agonist combining GLP-1 and glucagon receptor activation, with particular research focus on liver fat and energy expenditure.
Research suggests: Phase 3 trials (the SYNCHRONIZE program) are evaluating survodutide for weight loss and liver-fat reduction, building on earlier Phase 2 findings that showed notable results in NASH research populations.
Best for: Metabolic liver disease and obesity researchers
Key thing to know: Not approved; the glucagon receptor component directly targets liver fat accumulation, the primary differentiator from pure GLP-1 agents like semaglutide.
What is Survodutide?
Survodutide (formerly BI 456906) is an investigational dual receptor agonist developed by Boehringer Ingelheim that targets both GLP-1 and glucagon receptors. That combination sets it apart within the growing field of multi-receptor metabolic agents. Where tirzepatide pairs GLP-1 with GIP, survodutide pairs GLP-1 with glucagon, producing a different metabolic profile with particular interest for liver fat and energy expenditure.
Survodutide is being studied for two indications: obesity and non-alcoholic steatohepatitis (NASH), also called metabolic-associated steatohepatitis (MASH). NASH is a major unmet need — it can progress to cirrhosis and liver failure, with few established treatments. Survodutide's glucagon receptor component produces direct effects on hepatic lipid metabolism that make it a mechanistically compelling candidate.
It is not approved and remains an investigational compound. Phase 3 trials (the SYNCHRONIZE program for obesity and the LIVERAGE program for liver disease) are ongoing.
How it works.
In research, the proposed mechanism has several parts.
GLP-1 action: GLP-1 receptor agonism reduces appetite by acting on brainstem and hypothalamic circuits, slows gastric emptying, and improves glucose-dependent insulin secretion. These are the same mechanisms shared with semaglutide and tirzepatide, representing survodutide's appetite and glycemic component.
The glucagon component: The glucagon receptor agonism adds a distinct second mechanism. Glucagon is mainly known for raising blood glucose, but in obesity and liver disease its receptor activation also brings metabolic benefits: increased energy expenditure, fat breakdown (lipolysis), and direct hepatic effects that reduce liver fat accumulation.
Liver effects: These hepatic effects are particularly relevant to NASH, where excess liver fat is the defining pathological feature.
In plain terms: Think of GLP-1 as managing appetite and blood sugar while glucagon signals the liver to stop accumulating fat and burn more. With both active, the result is greater total fat loss and liver-fat reduction than GLP-1 alone. In most people, the GLP-1 component's insulin activity offsets glucagon's glucose-raising effect, though this balance needs monitoring in diabetes.
What the research shows.
The research evidence breaks down as follows.
Phase 3 (SYNCHRONIZE): Phase 3 trials (the SYNCHRONIZE program) are evaluating survodutide for both obesity and metabolic liver disease, building on earlier Phase 2 data that showed dose-dependent weight loss competitive with leading GLP-1 agents.
What the data shows: These results establish survodutide as a genuine contender in both obesity and NASH treatment research. The dual indication potential is scientifically significant because obesity and NASH frequently co-occur, and a single agent capable of addressing both would represent a meaningful clinical advance. Phase 3 trials are underway for both indications.
The limitation: The key limitation is that Phase 3 data is not yet available. Phase 2 trials, while well-designed, involve smaller populations and shorter durations than are required to establish efficacy and safety for regulatory approval. Long-term cardiovascular outcomes, durability of liver histology improvements, and safety in broader populations remain open questions.
Biomarkers to review first.
Research protocols for survodutide reference the following biomarkers as important baseline context. Given its dual effects on metabolic function and liver fat, both metabolic and liver markers are relevant before any protocol consideration.
How it compares to other compounds.
Survodutide is most often discussed in the research literature in comparison to other leading metabolic agents rather than in combination with them. The compounds below are the primary reference points researchers use to contextualise survodutide's efficacy and mechanism.
Goals & biomarkers connected to this peptide.
Go deeper
How survodutide's GLP-1 and glucagon dual mechanism fits within the broader metabolic peptide class.
Read Research →